Baidu
map

Stroke:肺炎并发脑卒中的病原学分析!

2018-06-18 xing.T MedSci原创

尽管分析受到小样本和异质性研究人群的限制,本文认为需氧革兰阴性杆菌和革兰阳性球菌常与肺炎合并卒中有关。这支持需要设计适当的研究来确定微生物病因和抗生素治疗方法。

识别肺炎并发脑卒中的病原体存在挑战,使用的抗生素往往是广谱的,并未特异性地针对病原体。近日,卒中领域权威杂志Stroke上发表了一篇研究文章,研究人员通过审查现有的文献,旨在明确引起肺炎并发卒中的微生物,然后制定公认的抗生素治疗方法。

研究人员根据Cochrane和PrimMA(系统评价和Meta分析的优选报告项目)指南对多个电子数据库使用预定检索标准进行系统文献回顾。纳入了缺血性卒中、脑出血或两者成年住院患者的研究,这些研究确定了肺炎并发卒中的微生物病因。

该分析共纳入了十五项研究(40%缺血性卒中、60%缺血性脑卒中和脑出血)的7968例患者。各研究间报告的肺炎发生率(2%-63%)有所差异,所有研究的合并频率为23%(95%可信区间为14%-34%;I2=99%)。大多数肺炎发生在卒中1周内(78%)。报告的细胞培养阳性的频率(15%-88%)变化较大。需氧革兰阴性杆菌(38%)和革兰阳性球菌(16%)培养最为常见;常见的菌种为肠杆菌科(21.8%:肺炎克雷伯菌占12.8%,大肠杆菌占9%)、金黄色葡萄球菌(10.1%)、铜绿假单胞菌(6%)、鲍曼不动杆菌(4.6%)和肺炎链球菌(3.5%)。痰液最常用于分离病原体(40%),或与气管抽吸也(15%)或血液培养相结合(20%)。

由此可见,尽管分析受到小样本和异质性研究人群的限制,本文认为需氧革兰阴性杆菌和革兰阳性球菌常与肺炎合并卒中有关。这支持需要设计适当的研究来确定微生物病因和抗生素治疗方法。

原始出处:

Amit K. Kishore, et al. Microbiological Etiologies of Pneumonia Complicating Stroke A Systematic Review.Stroke. 2018. https://doi.org/10.1161/STROKEAHA.117.020250

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-25 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-25 1e1bd0a6m50(暂无匿称)

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-20 gjsgj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-19 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-18 天地飞扬

    了解一下.谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-18 131****2916

    不错的文章值得推荐一下了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-18 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-18 1e0f8808m18(暂无匿称)

    学习了.谢谢分享了.

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1758000, encodeId=bfbe1e580008b, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jun 25 16:21:00 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=326887, encodeId=e6ef32688e53, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad451997581, createdName=1e1bd0a6m50(暂无匿称), createdTime=Mon Jun 25 11:49:29 CST 2018, time=2018-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586679, encodeId=036415866e9ae, content=<a href='/topic/show?id=fedfe08121c' target=_blank style='color:#2F92EE;'>#病原学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70812, encryptionId=fedfe08121c, topicName=病原学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff17366145, createdName=gjsgj, createdTime=Wed Jun 20 12:21:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026080, encodeId=e3cb102608029, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Jun 19 00:21:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325221, encodeId=94923252212a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Jun 18 23:19:51 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325212, encodeId=c5d432521266, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Jun 18 22:39:01 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325204, encodeId=e75c32520483, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Mon Jun 18 22:20:32 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325193, encodeId=6c1a3251932e, content=学习了.谢谢分享了., beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jun 18 21:45:18 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=325185, encodeId=5ac832518556, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50432048352, createdName=1811eb43e8m, createdTime=Mon Jun 18 21:26:04 CST 2018, time=2018-06-18, status=1, ipAttribution=)]
    2018-06-18 1811eb43e8m

    不错

    0

相关资讯

Eur Respir J:慢性阻塞性肺疾病患者血液嗜酸性粒细胞计数与肺炎住院风险!

在COPD和FEV1<50%预测值的个体中,血液嗜酸性粒细胞计数超过0.34×109个细胞/L与肺炎的高住院风险有关。

J Asthma:气流阻塞抗性儿童临床特性分析

最近,有研究人员鉴定了患有气流受限且对支气管扩张剂(BD)治疗具有抗性儿童的相关特性。研究鉴定了582名儿童。平均年龄为13岁(IQR: 11, 16),其中60%为男性;62%为白种人,28%为非裔美国人;19%为肥胖;32%为早产儿和21%的接触二手烟。肺部诊断包括了哮喘(93%),之前严重的肺炎(28%)和支气管扩张(5%)。65%报道具有过敏性鼻炎,11%患有慢性鼻窦炎。没有哮喘历史的参与

肺炎链球菌耐药性问题日益严重,专家建议及早预防接种

肺炎球菌性疾病是全球严重的公共卫生问题之一,也是导致我国5岁以下儿童死亡的重要原因,另外,这也是其他免疫力低下或障碍人群如老年人等易发生的疾病。临床治疗以抗生素为主,由于抗生素的广泛应用,肺炎链球菌的耐药性问题日益严重,为临床治疗带来挑战。因此,采用肺炎球菌疫苗预防肺炎球菌性疾病,尤为必要和迫切。为进一步提高中国北方地区免疫预防专业水平,提升各级疾病预防控制专业管理人员免疫预防相关知识和专业技能

Front Microbiol:研究发现PutA在铜绿假单胞菌感染肺炎中发挥重要的作用

铜绿假单胞菌是一种革兰氏阴性机会致病菌,可导致急性和慢性感染。感染宿主后,铜绿假单胞菌可改变基因表达以适应宿主环境并避免被宿主免疫系统清除。脯氨酸利用A(PutA)是将脯氨酸转化为谷氨酸的双功能酶。本研究中,研究人员发现PutA是小鼠急性肺炎模型中铜绿假单胞菌发挥毒力所必需的。 研究结果显示,与野生型菌株相比,putA突变体对氧化应激更敏感。AraC/XylS家族蛋白成员——PruR直接与p

Eur Respir J:低剂量CT在老年肺炎诊断中的应用!

由此可见,LDCT在很大比例的患者中改变了肺炎估计的概率。它主要有助于排除肺炎的诊断,从而减少不必要的AT。

PLOS ONE:中草药治疗肺癌患者的放射性肺炎效果

放射性肺炎是放射治疗常见的严重并发症。许多已发表的随机对照研究(RCTs)揭示了使用草药作为预防放射性肺炎的辅助治疗的增长趋势。

Baidu
map
Baidu
map
Baidu
map